

Nucynta ER - (50,100,150,200,250 mg; Tablet, Extended Release)

| | | | |
|------------------------------|--|-----------------------------|-----------------------|
| Generic Name | Tapentadol Hydrochloride | Innovator | ASSERTIO Therapeutics |
| Dosage | 50,100,150,200,250 mg; Tablet, Extended Release | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | Indicated for the management of moderate to severe acute pain in adults. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.